Ardelyx (ARDX) Competitors $5.01 +0.07 (+1.42%) Closing price 10/13/2025 04:00 PM EasternExtended Trading$5.08 +0.08 (+1.50%) As of 04:15 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ARDX vs. ARWR, ACLX, KYMR, PTGX, CRNX, ZLAB, AKRO, ACAD, AAPG, and MIRMShould you be buying Ardelyx stock or one of its competitors? The main competitors of Ardelyx include Arrowhead Pharmaceuticals (ARWR), Arcellx (ACLX), Kymera Therapeutics (KYMR), Protagonist Therapeutics (PTGX), Crinetics Pharmaceuticals (CRNX), Zai Lab (ZLAB), Akero Therapeutics (AKRO), ACADIA Pharmaceuticals (ACAD), Ascentage Pharma Group International (AAPG), and Mirum Pharmaceuticals (MIRM). These companies are all part of the "pharmaceutical products" industry. Ardelyx vs. Its Competitors Arrowhead Pharmaceuticals Arcellx Kymera Therapeutics Protagonist Therapeutics Crinetics Pharmaceuticals Zai Lab Akero Therapeutics ACADIA Pharmaceuticals Ascentage Pharma Group International Mirum Pharmaceuticals Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Ardelyx (NASDAQ:ARDX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, media sentiment, earnings and valuation. Which has preferable valuation and earnings, ARWR or ARDX? Ardelyx has higher revenue and earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Ardelyx, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArrowhead Pharmaceuticals$3.55M1,411.81-$599.49M-$1.28-28.32Ardelyx$333.61M3.62-$39.14M-$0.23-21.78 Is ARWR or ARDX more profitable? Arrowhead Pharmaceuticals has a net margin of 0.00% compared to Ardelyx's net margin of -14.60%. Ardelyx's return on equity of -36.57% beat Arrowhead Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Arrowhead PharmaceuticalsN/A -40.91% -11.62% Ardelyx -14.60%-36.57%-13.42% Does the media refer more to ARWR or ARDX? In the previous week, Arrowhead Pharmaceuticals had 1 more articles in the media than Ardelyx. MarketBeat recorded 13 mentions for Arrowhead Pharmaceuticals and 12 mentions for Ardelyx. Ardelyx's average media sentiment score of 0.59 beat Arrowhead Pharmaceuticals' score of 0.55 indicating that Ardelyx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ardelyx 2 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals have more ownership in ARWR or ARDX? 62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. Comparatively, 58.9% of Ardelyx shares are owned by institutional investors. 4.3% of Arrowhead Pharmaceuticals shares are owned by company insiders. Comparatively, 4.8% of Ardelyx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more risk & volatility, ARWR or ARDX? Arrowhead Pharmaceuticals has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500. Comparatively, Ardelyx has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500. Do analysts recommend ARWR or ARDX? Arrowhead Pharmaceuticals currently has a consensus price target of $43.14, indicating a potential upside of 19.01%. Ardelyx has a consensus price target of $11.70, indicating a potential upside of 133.53%. Given Ardelyx's stronger consensus rating and higher probable upside, analysts clearly believe Ardelyx is more favorable than Arrowhead Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arrowhead Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 2.78Ardelyx 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 2.91 SummaryArdelyx beats Arrowhead Pharmaceuticals on 10 of the 16 factors compared between the two stocks. Get Ardelyx News Delivered to You Automatically Sign up to receive the latest news and ratings for ARDX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARDX vs. The Competition Export to ExcelMetricArdelyxMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.19B$2.61B$6.05B$10.30BDividend YieldN/A57.78%5.73%4.82%P/E Ratio-21.7822.5785.1927.10Price / Sales3.62755.26597.83133.24Price / CashN/A26.3325.7730.18Price / Book6.865.3512.626.69Net Income-$39.14M$33.06M$3.32B$276.55M7 Day Performance-3.09%0.13%-0.04%-0.40%1 Month Performance-24.21%9.75%8.73%6.53%1 Year Performance-16.36%-1.04%78.10%41.04% Ardelyx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARDXArdelyx4.3325 of 5 stars$5.01+1.4%$11.70+133.5%-17.1%$1.19B$333.61M-21.7890News CoverageARWRArrowhead Pharmaceuticals4.0271 of 5 stars$37.50+3.8%$43.14+15.0%+96.6%$4.99B$3.55M-29.30400ACLXArcellx2.0189 of 5 stars$84.38-0.8%$114.31+35.5%+0.0%$4.72B$107.94M-24.6780Analyst RevisionKYMRKymera Therapeutics1.3652 of 5 stars$57.55-0.6%$61.26+6.5%+33.0%$4.14B$47.07M-16.58170PTGXProtagonist Therapeutics1.6737 of 5 stars$64.14-1.1%$68.36+6.6%+75.6%$4.03B$434.43M91.63120Analyst ForecastCRNXCrinetics Pharmaceuticals3.7167 of 5 stars$41.68+2.0%$74.45+78.6%-16.4%$3.85B$1.04M-10.14210ZLABZai Lab2.6073 of 5 stars$33.31-1.3%$56.35+69.2%+23.3%$3.77B$398.99M-16.331,869News CoveragePositive NewsAKROAkero Therapeutics3.6815 of 5 stars$46.04-0.1%$81.14+76.2%+81.1%$3.69BN/A-23.0230Analyst DowngradeACADACADIA Pharmaceuticals4.5097 of 5 stars$21.59-1.0%$29.12+34.9%+34.5%$3.68B$957.80M16.23510Gap UpAAPGAscentage Pharma Group InternationalN/A$39.86+1.2%N/AN/A$3.67B$134.35M0.00600Gap UpMIRMMirum Pharmaceuticals3.3418 of 5 stars$72.53-0.6%$76.50+5.5%+79.9%$3.66B$336.89M-59.94140 Related Companies and Tools Related Companies ARWR Competitors ACLX Competitors KYMR Competitors PTGX Competitors CRNX Competitors ZLAB Competitors AKRO Competitors ACAD Competitors AAPG Competitors MIRM Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARDX) was last updated on 10/14/2025 by MarketBeat.com Staff From Our PartnersREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredWhat if your job didn’t matter — and neither did China’s chip ban?If you’ve been watching the headlines lately…You’ve seen how Nvidia and AMD just got the green light to resume...Timothy Sykes | SponsoredAI's Next Magnificent SevenThe original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneInvestors are quietly piling into this secret AI stock Elon hates… It's one of those things you just need t...Economic Media | SponsoredThe Army Just Got a New Drone SupplierA cutting-edge drone developer just secured a U.S. Army deal to supply its Flex FPV Modular Drones and build a...The Tomorrow Investor | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ardelyx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ardelyx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
